Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma

Conclusion.MDM2 amplification levels in DDLPS follow a reproducible distribution and are associated with clinical outcomes and drug sensitivity. These results suggest that a prospective study of MDM2 as a predictive biomarker in DDLPS is warranted.Implications for Practice.No validated biomarkers exist for treatment selection in dedifferentiated liposarcoma (DDLPS). Although murine double minute 2 (MDM2) is currently used for diagnosis, the clinical relevance of MDM2 amplification has yet to be fully assessed. This study found that MDM2 amplification follows a predictable distribution in DDLPS and correlates with clinical and biological outcomes. These data suggests that MDM2 amplification may be a useful biomarker in DDLPS.

Source: The Oncologist - July 16, 2019 Category: Cancer & Oncology Authors: Kate Lynn J. Bill, Nathan D. Seligson, John L. Hays, Achal Awasthi, Bryce Demoret, Colin W. Stets, Megan C. Duggan, Manojkumar Bupathi, Guy N. Brock, Sherri Z. Millis, Reena Shakya, Cynthia D. Timmers, Paul E. Wakely Jr., Raphael E. Pollock, James L. Chen Tags: Sarcomas Source Type: research